{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T11:12:34Z","timestamp":1719659554454},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.remn.2016.05.004","type":"journal-article","created":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T05:27:33Z","timestamp":1468646853000},"page":"13-19","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radioinmunoterapia en el linfoma no Hodgkin, posicionamiento, seguridad y eficacia de 90Y-ibritumomab. Experiencia y seguimiento a los 10 a\u00f1os"],"prefix":"10.1016","volume":"36","author":[{"given":"A.","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mart\u00ednez-Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Mart\u00ednez-Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Beneit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Clavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Verd\u00fa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2016.05.004_bib0155","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica. Linfoma no Hodgkin [consultado Nov 2015]. Disponible en: http:\/\/www.seom.org\/es"},{"key":"10.1016\/j.remn.2016.05.004_bib0160","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for stage i-ii follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.remn.2016.05.004_bib0165","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.remn.2016.05.004_bib0170","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.remn.2016.05.004_bib0175","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/cncr.22066","article-title":"Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma","volume":"107","author":"Welgert","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.remn.2016.05.004_bib0180","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdh406","article-title":"Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol."},{"key":"10.1016\/j.remn.2016.05.004_bib0185","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.remn.2016.05.004_bib0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1157\/13083351","article-title":"Radioinmunoterapia en los linfomas no Hodgkin: desarrollo hist\u00f3rico y estado actual","volume":"25","author":"Emmanouilides","year":"2006","journal-title":"Rev Esp Med Nucl"},{"key":"10.1016\/j.remn.2016.05.004_bib0195","first-page":"199","article-title":"Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma","volume":"2","author":"Lehnert","year":"2009","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.remn.2016.05.004_bib0200","first-page":"1507","article-title":"Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice","volume":"43","author":"Juweid","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.remn.2016.05.004_bib0205","unstructured":"Non Hodgkin Lymphoma v4.2014. Clinical Practice Guideline. National Comprehensive Cancer Network (NCCN) [consultado 15 Dic 2014]. Disponible en: http:\/\/www.nccn.org"},{"issue":"S-6","key":"10.1016\/j.remn.2016.05.004_bib0210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/mdr388","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice. Guidelines for diagnosis, treatment and follow up","volume":"22","author":"Dreyling","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.remn.2016.05.004_bib0215","unstructured":"GPC-LF. Gu\u00eda de pr\u00e1ctica cl\u00ednica para el tratamiento de pacientes con linfoma folicular. Grupo GELTAMO y Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia. 2011 [consultado 10 Ene 2015]. Disponible en: 0http:\/\/www.guiasalud.es\/GPC\/GPC_474_Linfoma_folicular.pdf"},{"key":"10.1016\/j.remn.2016.05.004_bib0220","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE v 4.0). National Cancer Institute, Cancer Therapy Evaluation Program: 2010 [consultado 15 Feb 2013]. Disponible en:http:\/\/ctep.cancer.gov.\/forms\/ctcae3.pdf"},{"key":"10.1016\/j.remn.2016.05.004_bib0225","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.remn.2016.05.004_bib0230","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.remn.2016.05.004_bib0235","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.remn.2016.05.004_bib0240","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular or transformed non-Hodgkin's lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.remn.2016.05.004_bib0245","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmuntherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.remn.2016.05.004_bib0250","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remn.2016.05.004_bib0255","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: Differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.remn.2016.05.004_bib0260","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: Results from a multicenter study","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.remn.2016.05.004_bib0265","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.remn.2016.05.004_bib0270","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remn.2016.05.004_bib0275","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"90 yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma: 30 months of follow-up from an international multicenter phase ii clinical trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remn.2016.05.004_bib0280","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.remn.2016.05.004_bib0285","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90 yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma. Updated results after a median follow-up of 7.3 years from the international, randomized, phase iiifirst-line indolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remn.2016.05.004_bib0290","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00277-014-2145-6","article-title":"Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life","volume":"93","author":"Andrade-Campos","year":"2014","journal-title":"Ann Hematol."},{"key":"10.1016\/j.remn.2016.05.004_bib0295","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.2013.50.3110","article-title":"Fractionated 90 Y-ibritumomab Tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: An international phase ii study in patients requiring treatment according to GELF\/BNLI Criteria","volume":"32","author":"Illidge","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remn.2016.05.004_bib0300","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3324\/haematol.2013.093450","article-title":"Autologus stem cells transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: Results of a prospective, multicenter, phase ii clinical trial","volume":"99","author":"Briones","year":"2014","journal-title":"Haematologica."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X16300312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X16300312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T07:48:55Z","timestamp":1718696935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253654X16300312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S2253654X16300312"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2016.05.004","relation":{},"ISSN":["2253-654X"],"issn-type":[{"value":"2253-654X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioinmunoterapia en el linfoma no Hodgkin, posicionamiento, seguridad y eficacia de 90Y-ibritumomab. Experiencia y seguimiento a los 10 a\u00f1os","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2016.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y SEMNIM. All rights reserved.","name":"copyright","label":"Copyright"}]}}